Novartis, Sun Settle IP Suit Over Generic Focalin

Law360, New York (June 14, 2011, 4:58 PM EDT) -- Novartis Pharma AG resolved a patent infringement suit Monday in New Jersey over Sun Pharmaceutical Industries Ltd.'s proposed generic version of Novartis' attention deficit disorder drug Focalin after receiving government approval of a settlement agreement.

U.S. District Judge Susan D. Wigenton signed off on the agreement after counsel for the parties sent her a letter Thursday saying a regulatory review of the settlement, tentatively reached in March, had been completed.

"We are pleased to inform the court that plaintiffs and defendant Sun Pharmaceutical Industries Inc. have...
To view the full article, register now.